Media stories about Amphastar Pharmaceuticals (NASDAQ:AMPH) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Amphastar Pharmaceuticals earned a news impact score of 0.24 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 47.0948640959541 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Several equities analysts have recently commented on the company. BMO Capital Markets reiterated a “market perform” rating and set a $19.00 price objective (up from $17.00) on shares of Amphastar Pharmaceuticals in a research report on Tuesday, March 13th. BidaskClub upgraded Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, March 13th. Needham & Company LLC reiterated a “buy” rating and set a $24.00 price objective (up from $23.00) on shares of Amphastar Pharmaceuticals in a research report on Tuesday, March 13th. Wells Fargo reiterated a “buy” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, March 21st. Finally, Zacks Investment Research lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 13th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $21.33.
Shares of Amphastar Pharmaceuticals stock opened at $19.01 on Friday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.85 and a current ratio of 2.79. The stock has a market cap of $887.15, a PE ratio of 50.03, a PEG ratio of 1.36 and a beta of 1.42. Amphastar Pharmaceuticals has a 12 month low of $13.15 and a 12 month high of $20.45.
In related news, insider Jason B. Shandell sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 20th. The stock was sold at an average price of $19.43, for a total transaction of $388,600.00. Following the transaction, the insider now directly owns 251,372 shares in the company, valued at approximately $4,884,157.96. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO William J. Peters sold 19,801 shares of the firm’s stock in a transaction that occurred on Tuesday, March 13th. The stock was sold at an average price of $20.10, for a total value of $398,000.10. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 84,387 shares of company stock worth $1,659,763. 11.10% of the stock is owned by corporate insiders.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.